Exelixis, Inc. (NASDAQ:EXEL) Director George Poste recently disclosed a significant stock transaction, as detailed in a Form 4 filing with the U.S. Securities and Exchange Commission. On May 16, Poste sold 20,634 shares of Exelixis common stock at an average price of $45.99 per share, totaling approximately $948,957. The transaction comes as the company, now valued at $12.36 billion, has seen its stock surge 117% over the past year. According to InvestingPro analysis, Exelixis boasts a perfect Piotroski Score of 9, indicating exceptional financial strength.
The transaction followed Poste’s exercise of options to acquire the same number of shares at $19.77 each, a move that reflects a common practice of converting stock options into common shares before a sale. After these transactions, Poste holds 169,020 shares, including restricted stock units that have yet to vest. The timing is notable as the stock trades near its 52-week high, with InvestingPro data showing management has been actively buying back shares. Investors can access 14 additional key insights and a comprehensive Pro Research Report covering Exelixis on InvestingPro.
In other recent news, Exelixis reported strong first-quarter 2025 financial results, surpassing consensus expectations with revenues of approximately $555.4 million and non-GAAP earnings per share of $0.62. This performance led the company to raise its full-year revenue guidance to a range of $2.25 to $2.35 billion. Stifel analysts highlighted Exelixis’s Cabometyx sales, which reached $511 million, marking a 36% year-over-year increase and prompting a revision of the stock price target to $38. TD Cowen also increased its price target to $44, citing robust quarterly results and potential revenue growth, particularly in the treatment of neuroendocrine tumors (NET).
RBC Capital maintained an Outperform rating with a $40 price target, emphasizing the strong performance of the Cabozantinib franchise and the impact of the NET launch. Lucid (NASDAQ:LCID) Capital raised its price target to $37, maintaining a Neutral rating, while noting the company’s increased market share and the ongoing share repurchase program. JMP Securities adjusted its price target to $47, recognizing better-than-expected sales for cabozantinib and a significant increase in the full-year guidance. These developments reflect a positive outlook from analysts on Exelixis’s financial trajectory and market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.